FreeStyle Libre Pro Use in Primary & Secondary Care

Inclusion criteria

• Age at least 18 years.
• Type 2 diabetes treated with insulin therapy for at least 6 months prior to study enrolment.
• HbA1c between 58 and 108 mmol/mol (7.5 and 12.0%) inclusive.

Exclusion criteria

• Age at least 18 years.
• Type 2 diabetes treated with insulin therapy for at least 6 months prior to study enrolment.
• HbA1c between 58 and 108 mmol/mol (7.5 and 12.0%) inclusive.
• Participant is currently prescribed animal insulin.
• Total daily dose of insulin (TDD) is >1.75 iu/kg at entry to the study.
• Concomitant disease or condition that may compromise patient safety including and not limited to; cystic fibrosis, severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long term medical condition.
• Has a pacemaker or any other neurostimulators.
• Currently prescribed oral, intramuscular or intravenous steroid therapy for any acute or chronic condition or requires it during the study period.
• Currently receiving dialysis treatment or planning to receive dialysis during the study.
• Women who are pregnant, plan to become pregnant or become pregnant during the study.
• Participating in another study of a glucose monitoring device or drug that could affect glucose measurements or management.
• Currently using / has previously used a sensor based Glucose Monitoring System (including retrospective glucose monitoring system) within the last 6 months.
• Currently using Continuous Subcutaneous Insulin Infusion (CSII).
• Known (or suspected) allergy to medical grade adhesives.
• In the investigator's opinion the participant is unsuitable to participate due to any other cause/reason.